FDA
-
-
-
-
-
-
-
Vericel Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Vericel Reports Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
-
-
-
-
-
-
-
Vericel (VCEL) Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
-
-
-
-
-
-
-
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
-
-
-
-
-
-
-
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
-
-
-
-
-
-
-
MediWound (MDWD) Announces FDA Acceptance of BLA for NexoBrid
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

